What's New on Interventions for Lower Limb Spasticity?

Slides:



Advertisements
Similar presentations
Multimodal Management of Opioid-Induced Constipation
Advertisements

Applying the New Multiple Sclerosis Guidelines to Clinical Practice
New Horizons for SMA.
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Emerging Concepts in Heart Failure
Clinical Trials in IBD.
Oral Anticoagulants and Reversal Agents
Current State of Hyperkalemia Management
Acute Heart Failure.
HCV: Who Should We Screen and Why?
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
Heart Rate, HF Admissions, and Readmissions
Overview of the Action Plan
Overview of the Action Plan
Disclaimer. LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL.
New Challenges Facing Multiple Sclerosis Nurses
Ask the Onychomycosis Expert, Part 2
Patient-Centered Care in Cystic Fibrosis
Strategies for Assessing and Preserving Function in ALS
Optimizing Outcomes in the Management of GIST
SGLT2 Inhibitors in the Modern Era: Why and Where?
Antithrombotics and PAD: A New Paradigm in Practice
Program Goal. Program Goal Current Stroke Guidelines: AHA/ASA.
A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.
Beyond Statin Therapy.
Challenges in Managing Progressive Multiple Sclerosis
IL-17 Inhibitors in the Management of Psoriatic Disease
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?
Patient-Centric Approach to the Management of Spasticity
Dispelling Myths and Misconceptions ACC/AHA 2013 Digoxin Guidelines for Heart Failure.
Are We Closer to Personalized Medicine in MS?
Seizures in the Elderly: Treatment and Special Considerations
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Management of Adolescents With Seizures
PCSK9 Inhibitors and Cardiovascular Outcomes
Understanding PAD.
Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.
Reversal Strategies for VKA: Truths and Misconceptions
Program Goals Disclaimer Overview Assessing Disease Activity.
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
Oral Prostanoids and PAH
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Factor Xa Inhibitors in PAD
When Is Intrathecal Drug Delivery Appropriate?
Updates on the Prevention and Management of CINV
Project sponsor: {insert name} Project team: November 2017
Program Goals Disclaimers Defining Refractory Seizures.
Current Challenges in Managing Hemophilia
Antithrombotic Therapy in PAD
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.
Clinical Challenges and Updates in Managing Seizure Clusters
Lipid Updates From Spring 2019
Renal Function and Myeloma Therapeutics
Selecting Treatment Approaches in Hemophilia
When Is Intrathecal Drug Delivery Appropriate?
So Many Guidelines, So Little Time:
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Issues in Patients With Severe Epilepsy
Updates on Dyslipidemia
Minimal Residual Disease and Hematologic Malignancies
Challenges and Emerging Solutions in Anemia Management Explored
Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study1  Gerard E Francisco, MD, Corwin.
Ask the Psoriasis Expert
Presentation transcript:

What's New on Interventions for Lower Limb Spasticity?

Program Goals

Disclaimers

Why Focus on Lower Limb Spasticity?

Approved Botulinum Toxins

AAN Guidelines on BoNT for Lower Limb Spasticity: 2008 Review

AAN Guidelines on BoNT for Lower Limb Spasticity: 2015 Update

AAN Guidelines on BoNT for Lower Limb Spasticity: Clinical Issues

Emerging Data: OnabotulinumtoxinA in the Lower Extremity – Study Design

Emerging Data: OnabotulinumtoxinA in the Lower Extremity – Results

More About GAS

On the Horizon: A2NTX

Update on Intrathecal Baclofen

Challenges of Intrathecal Baclofen

The Challenge: Assessing Functional Gain

Emerging Oral Therapy for Functional Gain

Emerging Oral Therapy for Functional Gain (cont)

A Closer Look at Outcome Measures

Summary and Key Points

References

References (cont)

References (cont)

Abbreviations